Connect with us

Technology

DAVION HEALTHCARE ANNOUNCES PROPOSED ACQUISITION OF HUMASKAN AND ESTABLISHMENT OF UK FINANCE SUBSIDIARY TO SUPPORT STRATEGIC ACQUISITION PROGRAMME

Published

4 months ago

on

DUBLIN, June 25, 2026 /PRNewswire/ — Davion Healthcare Plc (“Davion” or the “Company”), a next-generation digital healthcare company developing non-invasive remote health monitoring solutions for the early identification of medical anomalies associated with serious health conditions, today announces that it has entered into a share purchase agreement to acquire 100% of Humaskan Ltd (“Humaskan”), a medical technology company, focused on proprietary healthcare products and intellectual property.  

In addition, the Company announces the proposed establishment of a wholly owned United Kingdom subsidiary, Davion Healthcare Finance Ltd, which is intended to support the Group’s planned acquisition and expansion strategy across the United States and Europe.

As previously announced, Davion continues to execute its strategy of building a broader healthcare platform through a combination of product development, commercial infrastructure, strategic financing capability and selective acquisitions. The proposed acquisition of Humaskan follows the recently announced acquisition of Solar Medical and Chemical Limited, which is intended to establish Davion’s principal commercial and distribution platform in the United Kingdom.

Transaction Summary – Humaskan Acquisition

The proposed acquisition comprises the purchase of 100% of the issued share capital of Humaskan for total consideration of $60 million.

The consideration is proposed to be satisfied through:

$10 million in cash consideration; and$50 million through the issue of ordinary shares in Davion.

The equity consideration is proposed to be issued at a reference price of $13.00 per share and would be subject to a nine-month lock-up arrangement and orderly market disposal provisions thereafter.

Strategic Financing Initiative – Davion Healthcare Finance Ltd

To support the Company’s planned acquisition programme and provide additional acquisition funding flexibility, Davion intends to establish Davion Healthcare Finance Ltd as a wholly owned United Kingdom subsidiary.

Subject to market conditions, regulatory processes, final approvals and completion of transaction documentation, Davion Healthcare Finance Ltd anticipates establishing a corporate bond programme of up to £100 million.

The proposed programme is expected to comprise three intended series:

Series 1 – up to £30 million.
Series 2 – up to £30 million.
Series 3 – up to £40 million.

The Company currently expects the bonds to carry an indicative fixed coupon of 10.5% per annum and an intended maturity profile of five years.

The Company currently intends that the bonds will be offered exclusively to professional, sophisticated and institutional investors and will not be made available to retail investors.

Subject to final approvals and market conditions, the Company currently expects each bond series to apply for admission to trading on the Vienna Stock Exchange MTF platform and currently anticipates launch activities commencing in August 2026.

The Company intends that proceeds raised under the proposed programme will be directed toward the Group’s acquisition programme across the United States and Europe.

The Company currently expects that any bond programme would be structured through Davion Healthcare Finance Ltd as issuer, and that acquisition assets funded through the programme may form part of the overall Group structure while being subject to dedicated security arrangements in support of the financing programme.

Reasons for Acquisition and Financing Strategy

The Board believes the proposed acquisition of Humaskan, together with the proposed financing structure, has the potential to accelerate Davion’s broader healthcare platform strategy through the addition of complementary intellectual property, products and commercial opportunities while supporting disciplined capital deployment.

The combined strategy is intended to:

Broaden Davion’s healthcare technology and intellectual property portfolio;Expand the Group’s product development and manufacturing capabilities;Create additional routes for revenue growth and commercial expansion;Support acquisition opportunities across target healthcare sectors in Europe and the United States; andStrengthen the scalability and flexibility of the Group’s healthcare platform.

Completion of the Humaskan acquisition and implementation of any financing programme remain subject to completion of definitive documentation, regulatory considerations, and satisfaction of customary conditions.

Jack Kaye, CEO of Davion Healthcare Plc, commented:

“The proposed acquisition of Humaskan and the intended establishment of Davion Healthcare Finance Ltd reflect our strategy of building a broader and more scalable healthcare platform.

“We believe combining proprietary technologies, commercial capability, targeted acquisitions and access to long-term institutional capital has the potential to create a flexible foundation for future growth.

“Our intention is to create a financing platform capable of supporting disciplined acquisition activity whilst maintaining a long-term approach to value creation.”

The Company will provide further updates regarding the proposed acquisition, financing programme and anticipated implementation timetable in due course.

Contacts

Media Enquiries:
media@davionhealthcare.com

For more information please visit:
www.davionhealthcare.com

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as “believes,” “will,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, the results of product evaluations, studies, regulatory reviews and commercial adoption and/or other studies, clinical trials, the challenges inherent in new product development initiatives, the impact of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, and other risks discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time. Finally, the investing public is reminded that only announcements or information about Davion Healthcare Plc disseminated by the Company and bearing its name are considered official.

View original content:https://www.prnewswire.com/news-releases/davion-healthcare-announces-proposed-acquisition-of-humaskan-and-establishment-of-uk-finance-subsidiary-to-support-strategic-acquisition-programme-302808400.html

SOURCE DAVION HEALTHCARE PLC

Related Topics:
Continue Reading

Technology

LEAP Group Relaunches HumanView, a Growth Intelligence System Built to Explain Why Customers Behave the Way They Do

Published

2 hours ago

on

October 24, 2026

By

Reimagined from the ground up, HumanView pairs statistical modeling with expert analysts to turn millions of real-world customer signals into business decisions

LOUISVILLE, Ky., Oct. 23, 2026 /PRNewswire/ — LEAP Group today announced the relaunch of HumanView, its growth intelligence service. The new version has been rebuilt from the ground up and now has a dedicated home at leapgroupnetwork.com/humanview.

HumanView analyzes what customers say and do across social platforms, e-commerce sites, review platforms, search behavior and user-generated content, including signals from Reddit, TikTok, YouTube, Meta, Amazon and Walmart+ that general AI tools cannot always access. Because the data reflects unprompted, real-world behavior, it avoids the response bias built into surveys and focus groups.

The service works in three layers. HumanView captures signals at scale, decodes millions of records through validated statistical models such as regression, correlation and clustering, and then relies on experienced analysts to interpret the patterns. Clients receive clear, human-validated insights instead of another dashboard.

“Machines find the patterns. Humans find the point,” said Alan Gilleo, CEO at LEAP Group. “The first version of HumanView showed us how much customers reveal when nobody is asking them questions. This version is built to explain why they act the way they do, and to put those answers in front of everyone making decisions, from product to service to marketing.”

HumanView focuses on three areas:

Growth Intelligence: customer motivations and how people perceive a brand and its competitors

Market and Category Intelligence: product pain points, service friction, unmet needs and competitive gaps

Audience Intelligence: new segments, positioning opportunities and gaps in the market

Every model is designed and validated by data scientists and benchmarked before it informs a recommendation.

To learn more about HumanView, visit leapgroupnetwork.com/humanview.

About LEAP Group
LEAP Group is a boutique marketing agency holding company with offices in Louisville, Indianapolis, Cincinnati and Chicago. Guided by the belief that brands should “Market Less. Matter More.,” LEAP gives clients access to specialized experts across its entire network. Learn more at leapgroupnetwork.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-group-relaunches-humanview-a-growth-intelligence-system-built-to-explain-why-customers-behave-the-way-they-do-302918557.html

SOURCE LEAP Group

Continue Reading

Technology

STEPHEN A. SMITH ADDRESSES WHITE HOUSE DINNER ATTENDANCE, REAFFIRMS COMMITMENT TO HBCUs AND PROTECTING CORPORATE INVESTMENT IN BLACK EDUCATION

Published

3 hours ago

on

October 24, 2026

By

NEW YORK, Oct. 23, 2026 /PRNewswire/ — Stephen A. Smith, media mogul, New York Times bestselling author, and proud 1991 graduate of Winston-Salem State University, is addressing the public discussion surrounding his decision to attend a White House dinner with President Donald Trump, emphasizing his commitment to the long-term financial stability of Historically Black Colleges and Universities (HBCUs).

For Smith, the decision was rooted in a commitment to institutions that have educated generations of Black leaders, professionals, entrepreneurs, and public servants.

“I will always advocate for HBCUs and the students whose futures depend on them,” Smith said. “My reason for attending the White House dinner was to discuss the challenges these institutions face in securing long-term funding and to make the case that corporate America must continue to invest in them.”

Smith acknowledged federal support through the FUTURE Act while expressing concern that political tensions surrounding diversity, equity, and inclusion (DEI) could discourage private companies from supporting HBCUs. He maintains that these institutions deserve sustained corporate partnerships, philanthropic contributions, and public investment.

“If we truly believe in free-market capitalism, businesses should be able to support educational institutions and charitable causes without fear of criticism or repercussions,” Smith said. “HBCUs have made extraordinary contributions to this country. They deserve sustained public and private investment.”

Ashley Christopher, Esq., Founder and CEO of the HBCU Week Foundation, recognized Smith’s advocacy and decision to engage with the administration.

“Stephen A. Smith has been a powerful advocate for HBCUs, using his platform and influence to shine a national spotlight on our institutions,” expressed Christopher, “His continued support of HBCU Week helps advance our mission of connecting students with life-changing educational opportunities, and we are proud to have him as our ambassador.”

Since Smith became an HBCU Week Ambassador in 2019, the initiative has facilitated more than 15,000 on-the-spot college acceptances and raised and awarded more than $150 million in scholarships, according to the HBCU Week Foundation.

As public discussion continues, Smith is emphasizing the importance of ensuring HBCUs have the resources and partnerships needed to educate future generations and expand opportunities for students.

CLICK HERE to watch Smith’s full response to his White House visit.

MEDIA CONTACT:

media@mrsasinc.com

View original content:https://www.prnewswire.com/news-releases/stephen-a-smith-addresses-white-house-dinner-attendance-reaffirms-commitment-to-hbcus-and-protecting-corporate-investment-in-black-education-302918547.html

SOURCE Straight Shooter Media

Continue Reading

Technology

Advantex Announces Completion of Financing and Extension of Maturity Date of Previously Issued Debentures

Published

3 hours ago

on

October 24, 2026

By

TORONTO, Oct. 23, 2026 /CNW/ — Advantex Marketing International Inc. (CSE: ADX) (“Advantex”), a leader in the merchant cash advance and loyalty marketing products for merchants, today announced the completion of a $250,000 secured debt financing. Advantex issued a $250,000 non-convertible debenture which bears an interest rate at 12% per annum and matures December 15, 2027. The proceeds raised from this issuance of the Debenture will be used for working capital purposes.

Advantex has also extended the maturity of its existing $700,000 in 12% secured debentures from October 10, 2026 to December 15, 2027.

About Advantex Marketing International Inc.

Advantex provides working capital to merchants. Advantex also provides specialized marketing programs that enable members of Aeroplan to earn Aeroplan points at participating merchants.

Advantex shares trade on the Canadian Securities Exchange under the symbol ADX. For more information go to Advantex’s profile on www.sedar.com

Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of applicable securities laws relating to the future business and operations of Advantex. Actual results and developments may differ materially from those contemplated by these statements. The business and operations of Advantex described herein is dependent on a number of factors and is subject to a number of risks and uncertainties. Factors that could cause actual results to differ material include, but are not limited to, changes in Advantex’s economic and competitive conditions including but not limited to the industry sectors in which Advantex operates.

The statements in this news release are made of the date of this release. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date the statements are made and Advantex undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law.

SOURCE Advantex Marketing International Inc.

Continue Reading

Trending